The re-appointment was approved by the members of the Company at the 41st Annual General Meeting held on Friday, 21 August 2026. The approval covers a three-year term commencing from 28 October 2026 to 27 October 2029 (both days inclusive).
Key Details of Re-appointment:
- Reason for Change: Re-appointment approved by shareholders at AGM
- Date of Re-appointment: 28 October 2026
- Tenure: 3 years (28 October 2026 to 27 October 2029)
- Retirement Provision: Liable to retire by rotation
Professional Profile of Mr. Aalap Prajapati:
- Over 15 years of experience in the pharmaceutical sector
- Expertise in business strategy, operations management, marketing, and business development
- Holds a management qualification from B.K. School of Business Management with specialization in Marketing and Operations
- Actively associated with the Company's leadership and growth initiatives
- Plays a key role in driving operational efficiency and long-term business development
Director Relationships:
Mr. Aalap Prajapati is the son of Mr. Natwarbhai Prajapati, who is the Whole Time Director of the Company.
Compliance Status:
Mr. Aalap Prajapati is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.